KRON - Kronos Bio, Inc.
IEX Last Trade
0.9614
0.061 6.387%
Share volume: 6,795
Last Updated: Fri 27 Dec 2024 07:57:28 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.90
0.06
6.82%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-3.16%
1 Month
-4.18%
3 Months
-6.12%
6 Months
-23.33%
1 Year
-27.56%
2 Year
-40.26%
Key data
Stock price
$0.96
DAY RANGE
$0.90 - $0.94
52 WEEK RANGE
$0.76 - $1.60
52 WEEK CHANGE
-$26.40
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Norbert W. Bischofberger
Region: US
Website: kronosbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kronosbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. Its lead product candidate is entospletinib (ENTO), an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Recent news